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ABSTRACT
Sleeping sickness (trypanosomiasis) is a neglected tropical disease that affects mostly the poorest communities in sub-Saharan
Africa. Toxic side effects associated with the use of current anti-trypanosomal drugs, which in some cases kill faster than the
disease itself, necessitate the search for new drugs with better safety margins. To this effect, a small library bearing different
substituents at position -1, -3, and -6 of the quinolone nucleus were synthesized and evaluated in vitro against HeLa cell lines and
Trypanosoma brucei brucei for cytotoxicity and trypanocidal potentials, respectively. While most of these compounds showed no
cytotoxic effect, they exhibited moderate to weak anti-trypanosomal activities. The SAR studies of this series provide new infor-
mation worth considering in future exploration of the quinolone scaffold in search of more potent and safe trypanocidal agents.
KEYWORDS
Sleeping sickness, trypanosomiasis, quinolones, non-fluoroquinolones.
1. Introduction
Human African trypanosomiasis (HAT), also referred to as
sleeping sickness,1 is among the WHO’s list of neglected tropical
diseases (NTDs).2 It mostly affects people living in rural areas of
sub-Saharan Africa,3 where medical facilities are scarce and drug
purchasing power of inhabitants is very low.4 At least 2184 new
cases of the disease were reported in 2016,5 and approximately
60 million people living in 36 different countries are presently at
risk of contracting the disease.6
HAT takes two forms caused by two different subspecies of
Trypanosoma brucei.7 T. b. gambiense is the pathogenic subspecies
causing the form of HAT commonly found in central and
western Africa,8,9 whereas T. b. rhodesiense is the subspecies
responsible for the form of HAT prevalent in eastern and south-
ern Africa.10 It has been noted that the two sub-pathogenic
species coexist in Uganda.11 These pathogens are transmitted
between humans following the bite of an infected tsetse fly.12 The
disease exists in two stages:13,14 haemolymphatic stage – wherein
the parasites are localized in blood and lymphatic systems,15 and
an encephalitic stage – wherein the parasites have invaded the
central nervous system.16,17
Current treatment options are limited to just four drugs.18 In
any case of HAT, the drug to be used is dictated by the form and
stage of the disease. Pentamidine is the drug of choice for treat-
ing the haemolymphatic stage of HAT caused by T. b. gambiense,19
while a combination of nifurtimox and eflornithine is used to
treat the encephalitic stage.20 In cases of T. b. rhodesiense, suramin
is the recommended drug for treating the haemolymphatic
stage,21 while malarsoprol is used to treat the encephalitic stage.22
Besides limited treatment options, the foregoing drugs are far
from ideal. They all have poor oral bioavailability (and hence
are administered intravenously), and considerable toxic side
effects.23 For example, pentamidine causes hyper or hypoglycae-
mia and hypotension,24 suramin causes renal failure, eflor-
nithine causes alopecia and seizures,25 while at least 5.9 % of
patients on malarsoprol die from its toxicity,26 creating a scenario
wherein patients either die from an acute illness or die faster
from a pill.
The overwhelming life-threatening side effects of existing
drugs used to treat sleeping sickness create a dire need for new
compounds with better drug properties such as high oral
bioavailability, and a high safety margin. The therapeutic poten-
tials of quinolones cannot be over emphasized. Compounds
containing this scaffold are currently in use as drugs to treat
bacterial and viral infections as well as other conditions such as
cancers.27 Fluoroquinolones (Fig. 1a) in clinical use have been
extensively screened against trypanosomes and their activity
profiles established as moderate to poor.28,29,30 A hit optimization
study by Hiltensperger and co-workers generated a potent
library of fluoroquinolones characterized by benzylamides,
(a)cyclic amines, and aliphatic chains at positions -3, -7, and -1 of
the quinolone nucleus. However, the lead compound (Fig. 1b) in
this series suffers from poor solubility,31 necessitating further
work on this class of compounds. Unlike fluoroquinolones, the
anti-trypanosomal potentials of non-fluorinated quinolones
have not been extensively investigated, with just one study on
non-fluorinated quinolones bearing substituents at position -1
and -2, respectively, being reported32 (Fig. 1c). To further expand
the SAR around the non-fluoquinolone scaffold, we conceptual-
ized and synthesized a library of 18 non-fluorinated quinolones
bearing unique concurrent substituents at position -1, -3, and -6.
Target compounds were subjected to in vitro cytotoxicity and
anti-trypanosomal evaluation. At 20 µM concentration, most of
the compounds exhibited less than 50 % parasite viability while
having little effect on the viability of HeLa cell lines (see Supple-
mentary information). This suggests that the quinolone scaffold
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can be tailored via chemical synthesis to generate safe and potent
drug substrates to treat trypanosomiasis.
2. Results and Discussion
We conceptualized and synthesized a set of 18 novel com-
pounds that bear different substituents at positions -1, -3 and -6
of the quinolone scaffold. Conceptualized compounds were
synthesized as depicted in Scheme 1. Briefly, 4’-nitroaceto-
phenone was reduced to 4’-aminoacetophenone using reduced
iron powder and acetic acid.33 4’-Aminoacetophenone and
4-chloroaniline were each treated with diethyl ethoxy-
methylenemalonate in refluxing acetonitrile to form condensed
methylenemalonate esters, which underwent cyclization in
boiling diphenylether at 245–250 °C for 5 min to form compound
2. Deprotonation of 2 using K2CO3, followed by N-alkylation
with alkylhalides afforded target compounds 3a–h in yields
ranging between 40 and 70 %. Ester functionality in compounds
3d–h underwent selective aminolysis in the presence of a ketone
to afford target compounds 4a–j in 30–50 % yields. This transfor-
mation was realized using DBU as a base. All targeted com-
pounds were characterized using proton and carbon NMR,
HRMS and IR. The carbon NMR spectra of all compounds show
a peak at c. 174 ppm, which is indicative of an oxo carbon within
the quinolone nucleus (C-4) and the peak at c. 164 ppm is
assigned to ester or amide carbonyl carbon (C-3a). With the
exception of compounds 3a–c, the proton NMR spectra of all
compounds show a singlet signal at ~2.3–2.6 ppm, which is
assigned to a methyl attached to a carbonyl carbon (CH3C=O).
The carbonyl carbon is also evident in the respective carbon
spectra at ~197ppm. The presence of a triplet peak (J = 5.9 Hz) at
c. 9.9 ppm in the proton NMR spectra of compounds 4a–j, which
is absent in compounds 3d–h, suggests the successful conver-
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Figure 1 Representative structures of fluoroquinolones (a and b) and non-fluoroquinolones (c) investigated for anti-trypanosomal activities.
Scheme 1
Synthesis of target compounds
Reagents and conditions: (a) Acetonitrile, diethyl ethoxymethylenemalonate, reflux 12 h, (b) Diphenyl ether, 250 °C, 5 min,
(c) K2CO3, DMF, alkylhalide (1.2 eqv), 12 h, (d) Amine (5 eqv), DBU (1.2 eqv), CHCl3, reflux 12 h.
sion of ester to amide. It is also worth noting that the acquisi-
tion of NMR spectroscopic data was at times hindered by
compounds crystallizing out of the solutions. This sometimes
necessitated the use of hot solvents to encourage compounds
to remain in solution long enough to obtain 1H and 13C NMR
spectroscopic data (see Supplementary information). The ab-
sorption band at 1654/cm on the IR spectrum further confirms
the presence of amide.
This focused library was screened in vitro against human
cervix adenocarcinoma (HeLa) cell lines to investigate potential
cytotoxicity effects. The compounds were incubated at 20 µM in
96-well plates containing HeLa cells for 48 h. The numbers of
cells surviving upon drug exposure were determined using
resazurin reduction to resorufin by live cells and reading
resorufin fluorescence in a multiwell plate reader. Compounds
were tested in duplicate, and a standard deviation (S.D.) calcu-
lated. Results are expressed as % viability based on fluorescence
readings in treated wells versus untreated control wells. Emetine
(which induces cell apoptosis) was used as positive control. With
the exception of compound 4f (% viability, –19 %), and 4j (%
viability, –13 %), which strongly inhibited HeLa cell lines, the
rest of the series had little to no effect on HeLa cell viability. This
observation suggests that this series with necessary optimiza-
tion could serve as templates for the development of non-toxic
anti-trypanosomal agents.
The compounds were further evaluated in vitro for anti-
trypanosomal activities by screening against the 427 strain of T. b.
brucei. Compounds were added to in vitro cultures of T. b. brucei
in 96-well plates at a 20 µM concentration. After an incubation
period of 48 h, the numbers of parasites surviving drug exposure
were determined by adding resazurin. As in HeLa cells,
resazurin is reduced to resorufin by living parasites. Resorufin is
a fluorophore (Exc560/Em590) and can thus be quantified in a
multiwell fluorescence plate reader. Compounds were tested in
duplicate wells, and a standard deviation (S.D.) calculated.
Results are expressed as % viability – the resorufin fluores-
cence in compound-treated wells relative to untreated controls.
Pentamidine (an existing drug for treatment of trypanosomiasis)
was used as a positive control. At 20 µM concentration, 11
compounds inhibited parasite growth below 50 % (Table 1);
however, only compounds inhibiting parasite viability below
25 % with little or no effect on HeLa cell line were considered for
IC50 determination. The IC50 values for the selected compounds
are summarized in Fig. 2.
Structure–activity relationship analysis across this series
suggests that modifications at position -1, -3, and -6 of the
quinolone scaffold influence anti-trypanosomal activities. For
example, comparing the activity profiles of compounds 3b (IC50,
19 µM) and 3g (IC50, 24 µM), all having the same substituents at
position -1 and -3 and differing in substitution pattern only at
position -6 suggests that a chloride substituent at this position
leads to increase anti-trypanosomal activity than a ketone. Also,
comparing compounds 3d (IC50, 32 µM) bearing an alkyl chain at
position -1 and 3g (IC50, 24 µM) bearing a substituted-benzyl
moiety at position -1, indicates that the presence of a substi-
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Figure 2 Plot of percentage viability against log concentration for compound 3a, 3b, 3d, 3g, 4b and 4g as well as the standard (PE = pentamidine) and
their corresponding IC50 values.
Table 1 In vitro cytotoxicities and anti-trypanosomal activities of target
compounds expressed as percentage viabilities.
Comp. % Viability ± S.D.
T. b. brucei HeLa cells
3a 21.2 ± 4.0 97.6 ± 5.6
3b 4.0 ± 0.7 100.2 ± 6.2
3c 97.3±3.3 102.7 ± 7.6
3d 21.0 ± 3.7 77.0 ± 0.7
3e 43.8 ± 3.2 96.7 ± 3.7
3f 87.3 ± 7.0 107.2 ± 1.6
3g 5.5 ± 5.2 103.6 ± 3.7
3h 42.3 ± 8.4 108.6 ± 5.3
4a 95.4 ± 10 92.6 ± 3.6
4b 4.8 ± 0.1 86.1 ± 2.4
4c 105.8 ± 1.6 110.7 ± 6.7
4d 31.2 ± 12.2 88.9 ± 5.8
4e 100.0 ± 2.7 102.6 ± 5.7
4f -1.3 ± 0.3 -19.2 ± 0.04
4g 24.7 ± 7.6 102.1 ± 5.8
4i 64.5 ± 7.8 91.0 ± 4.9
4j 50.3 ± 4.4 -14.0 ± 0.6
PE a 0.0 N.D
EMT b N.D c 0.0
aPE = pentamidine, bEMT = ematine, cN.D = not determined.
tuted-benzyl moiety at position -1 seems to promote anti-
trypanosomal activities over alkyl chains. We also observed
that the substituent on the benzyl moiety at position -1 also
influences anti-trypanosomal activities. This is evident when
comparing the effects of compounds 3a, 3b and 3c on parasite
viability at a concentration of 20 µM. Compounds 3a and 3b
bearing -NO2, and -Br, respectively, exhibited more than 75 %
parasite growth inhibition, while compound 3c having -CF3
substituent exhibited less than 5 % parasite growth inhibition.
These results suggest that electron-withdrawing units promote
activity while electron-donating unit leads to poor activity. The
substitution pattern at position -3 also seems to greatly influence
activity. Comparing the activity of compounds 3g (IC50, 24 µM)
and 4g (IC50, 7 µM), both of which differ only in the substituent at
position -3, suggests that an amide moiety at position -3 seems
to enhance activity over ethyl ester.
3. Conclusion
We have synthesized a series of novel quinolones with varied
substituents at position -1, -3 and -6 of the quinolone scaffold.
While most compounds in this series showed no promising
cytotoxicity potentials, compounds 4g emerged as potent
anti-trypanosomal hit with IC50 value of 7 µM. Although this
series exhibited moderate to weak activities profiles, the compre-
hensive structure–activity relationship analyses of this series
will undoubtedly serve as a resource for further optimization of




All the chemicals and solvents used were purchased from
various chemical suppliers and were used without further puri-
fication. Melting points were determined using a Reichert hot
stage microscope and are uncorrected. The progress of the
reactions was monitored by thin layer chromatography (TLC)
using Merck F254 silica gel plates supported on aluminium. The
crude products were purified by a silica gel column chromatog-
raphy using Merck Kieselgel 60 Å: 70–230 (0.068–0.2 mm) silica
gel mesh. 1H and 13C NMR spectra were recorded on Bruker
Biospin 300 MHz, or 400 MHz spectrometers, and the chemical
shifts are given in d values referenced to solvents and are re-
ported in parts per million (ppm). The high-resolution mass
spectrometric data of final compounds was recorded on a Waters
Synapt G2 quadrupole time-of-flight (QTOF) mass spectro-
meter operated with an electrospray ionization probe in the
positive mode (University of Stellenbosch). The instrument was
operated with an electrospray ionization probe in the positive
mode. The starting quinolones 2 were synthesized from the
synthetically accessible compounds 1 as previously described in
literature.34
4.2. Synthesis of Compounds
4.2.1. General Method for the Preparation of N-alkylated Compounds
3a–h
A mixture of 2 (3.86 mmol, 1 g, 1 eq), K2CO3 (5.0 mmol, 0.53 g),
alkyl halide (5 eq.) in acetone (50 mL) was refluxed for 15 h. Upon
reaction completion as indicated by TLC, the mixture was
filtered, and the filtrate evaporated to dryness to obtain a crude
N-alkylated product which was purified through silica gel
column chromatography using CH2Cl2/MeOH (10:1) as the




Brown powder, 0.515 g (48 %), Rf = 0.81 (DCM/MeOH 10:1)
m.p. 153–155 °C; 1H NMR (300 MHz, DMSO) d 9.00 (s, 1H, H-2),
8.16 (d, J = 2.5 Hz, 1H, H-5), 7.89–7.57 (m, 3H, H-1c, H-8), 7.48
–7.05 (m, 3H, H-7, H-1d), 5.82 (s, 2H, H-1a), 4.24 (s, 3H, H-3c).
13C NMR (75 MHz, DMSO) d 172.2 (C-4), 164.1 (C-3a), 151.3 (C-2),
141.1 (C-3), 138.2 (C-6), 133.2 (C-1d), 131.3 (C-1c), 130.5 (C-5),
130.1 (C-7), 127.6 (C-1b), 126.3 (C-4a), 125.9 (C-8), 120.7 (C-8a),
110.9 (C-1e), 57.3 (C-3c), 55.7 (C-1a). IR (neat, cm–1): 3093, 2972,




White powder, 0.015 g (46 %), Rf = 0.8 (DCM/MeOH 10:1), m.p.
196–198 °C; 1H NMR (400 MHz, DMSO) d 8.94 (s, 1H, H-2), 8.16
(d, J = 2.5 Hz, 1H, H-5), 7.81–7.48 (m, 4H, H-7, H-8, H-1c), 7.21 (d,
J = 8.4 Hz, 2H, H-1d), 5.68 (s, 2H, H-1a), 4.25 (q, J = 7.1 Hz, 2H,
H-3c), 1.30 (t, J = 7.1 Hz, 3H, H-3d). 13C NMR (101 MHz, DMSO)
d 172.0 (C-4), 165.0 (C-3a), 151.0 (C-2), 138.5 (C-3), 135.5 (C-6),
132.9 (C-5), 132.2 (C-1d), 130.6 (C-1b), 129.9 (C-1c), 128.9 (C-4a),
125.9 (C-7), 121.8 (C-1e), 120.6 (C-8), 111.1 (C-8a), 60.3 (C-3c), 55.6
(C-1a), 14.2 (C-3d). IR (neat, cm–1): 3096, 2978, 2941, 1702, 1680.




Brown powder, 0.5 g (70 %), Rf = 0.81 (DCM/MeOH 10:1), m.p.
203–205 °C; 1H NMR (400 MHz, Pyridine) d 9.19 (s, 1H, H-2), 7.65
(d, J = 8.4 Hz, 2H, H-1c), 7.56–7.49 (m, 3H, H-5, H-7, H-8), 7.43 (d,
J = 8.4 Hz, 2H, H-1d), 5.00 (s, 2H, H-1a), 4.36 (q, J = 6.9 Hz, 2H,
H-3c), 1.23 (t, J = 6.9 Hz, 3H, H-3d). 13C NMR (101 MHz, Pyridine)
d 173.0 (C-4), 164.7 (C-3a), 150.64 (C-2), 140.6 (C-3), 140.2 (C-1b),
137.9 (C-6), 135.5 (C-1d), 132.9 (C-1c), 130.9 (C-5), 130.2 (C-7),
127.2 (C-1e), 126.4 (C-4a), 125.9 (C-8), 120.7 (C-8a), 119.5 (C-1f),
112.2 (C-1f), 60.3 (C-3c), 56.0 (C-1a), 14.2 (C-3d). IR (neat, cm–1):
3003, 2962, 2921, 1705, 1684, ESI-HRMS m/z [M+H]+ calcd for
C20H16ClF3NO3 410.0765, found 410.0766.
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Ethyl 6-acetyl-1-ethyl-4-oxo-1,4-dihydroquinoline-3-carboxylate, 3d
Red powder, 0.65 g (70 %), Rf = 0.71 (DCM/MeOH 10:1); m.p.
143–147 °C; 1H NMR (300 MHz, CDCl3) d 8.97 (s, 1H, H-2), 8.44 (d,
J = 2.1 Hz, 1H, H-5), 8.22 (dd, J = 8.9, 2.1 Hz, 1H, H-7), 7.46 (d, J =
9.0 Hz, 1H, H-8), 4.39–4.31 (m, 2H, H-1a), 4.23 (q, J = 7.2 Hz, 2H,
H-3c), 2.63 (s, 3H, H-6b), 1.50 (t, J = 7.3 Hz, 3H, H-3d), 1.37–1.20
(m, 3H, H-1b). 13C NMR (75 MHz, CDCl3) d 196.9 (6a), 173.9 (4),
165.4 (3a), 149.1 (2), 141.6 (3), 133.3 (6), 131.4 (5), 129.5 (7), 128.7
(4a), 116.2 (8), 112.4 (8a), 61.1 (3c), 49.1 (1a), 26.6 (6b), 14.5 (1b), 14.4
(3d). IR (neat, cm–1): 3053, 2982, 2921, 1712, 1685, ESI-HRMS m/z
[M+H]+ calcd for C16H18NO4 288.1230, found 288.1234.
Methyl 6-acetyl-4-oxo-1-(4-(trifluoromethyl)benzyl)-1,4-dihydro-
quinoline-3-carboxylate, 3e
Brown powder, 0.680 g (68 %), Rf = 0.81 (DCM/MeOH 10:1),
m.p. 133–136 °C; 1H NMR (300 MHz, DMSO) d 9.02 (s, 1H, H-2),
8.76 (d, J = 3.4 Hz, 1H, H-5) 8.15 (dd, J = 9.1, 3.4 Hz, 1H, H-7) , 7.73
(d, J = 8.0, Hz, 2H, H-1c), 7.60 (d, J = 7.1 Hz, 2H, H-1d) , 7.43 (d, J =
9.1 Hz, 1H, H-8), 5.82 (s, 2H, H-1a), 3.89 (s, 3H, H-3c), 2.49 (s, 3H,
H-6b). 13C NMR (75 MHz, DMSO) d 197.1 (C-6a), 173.9 (4), 164.4
(3a), 151.4 (C-2), 142.2 (C-3), 140.2 (C-1b), 135.7 (C-1d), 133.3
(C-6), 132.3 (C-1c), 132.0 (C-5), 129.2 (C-7), 128.2 (C-1e), 127.6
(C-4a), 121.5 (C-8), 118.8 (C-8a), 111.6 (C-1f), 55.3 (C-3c), 53.7
(C-1a), 26.6 (6b). IR (neat, cm–1): 3100, 2970, 2921, 1700, 1680.
ESI-HRMS m/z [M+H]+ calcd for C21H16F3NO4 404.1104, found
404.1107.
Ethyl 6-acetyl-1-benzyl-4-oxo-1,4-dihydroquinoline-3-carboxylate, 3f
White powder, 0.80 g (58 %), Rf = 0.81 (DCM/MeOH 10:1) m.p.
142–144 °C; 1H NMR (300 MHz, DMSO) d 9.00 (s, 1H, H-2), 8.81 (s,
1H, H-5), 8.19 (d, J = 8.8 Hz, 1H, H-8), 7.77 (d, J = 8.9 Hz, 1H, H-7),
7.49–7.21 (m, 5H, H-1c/H-1g), 5.77 (s, 2H, H-1a), 4.31 (q, J = 7.0
Hz, 2H, H-3c), 2.55 (s, 3H, H-6b), 1.40–1.26 (m, 3H, H-3d).
13C NMR (75 MHz, DMSO) d 197.1 (C-6a), 173.3 (C-4), 164.7
(C-3a), 151.1 (C-2), 142.4 (C-3), 136.2 (C-1b), 133.2 (C-6), 131.8
(C-5), 129.4 (C-1g), 128.4 (C-4a), 128.3 (C-1f), 127.7 (C-7), 126.9
(C-1e), 118.8 (C-8), 111.9 (C-8a), 60.5 (C-3c), 56.2 (C-1a), 27.2
(C-6a), 14.7 (C-3d). IR (neat, cm–1): 3083, 2970, 2921, 1705, 1681,




Brown powder, 0.58 g (62 %), Rf= 0.81 (DCM/MeOH 10:1), m.p.
173–175 °C; 1H NMR (300 MHz, DMSO) d 8.99 (s, 1H, H-2), 8.75 (s,
1H, H-5), 8.16 (d, J = 8.6 Hz, 1H, H-7), 7.81–7.52 (m, 3H, H-1c,
H-8), 7.19 (d, J = 7.6 Hz, 2H, H-1d), 5.72 (s, 2H, H-1a), 3.79 (s, 3H,
H-3c), 2.50 (s, 3H, H-6b). 13C NMR (75 MHz, DMSO) d 197.4
(C-6a), 173.1 (C-4), 166.4 (C-3a), 151.4 (C-2), 142.2 (C-3), 135.7
(C-1d), 133.3 (C-6), 132.3 (C-1c), 132.0 (C-5), 129.2 (C-7), 128.3
(C-1b), 127.6 (C-4a), 127.5 (C-8), 119.8 (C-8a), 111.6 (C-1e), 55.3
(C-3c), 53.7 (C-1a), 26.6 (6b). IR (neat, cm–1): 3048, 2972, 2931, 1702,




Brown powder, 0.28 g (48 %), Rf = 0.81 (DCM/MeOH 10:1),
m.p. 197–1199 °C; 1H NMR (300 MHz, DMSO) d 9.16 (s, 1H, H-2),
8.92 (d, J = 2.2 Hz, 1H, H-5), 8.26 (dd, J = 8.9, 2.2 Hz, 1H, H-7), 7.85
(d, J = 9.0 Hz, 1H, H-8), 7.72–7.59 (m, 2H, H-1d, H-1g), 7.21 (dd,
J = 8.3, 2.2 Hz, 1H, H-1f), 5.87 (s, 2H, H-1a), 3.77 (s, 3H, H-3c), 2.70
(s, 3H, H-6b). 13C NMR (75 MHz, DMSO) d 197.1 (C-6a), 176.3
(C-4), 164.0 (C-3a), 150.2 (C-2), 142.1 (C-3), 137.4 (C-6), 133.4
(C-1b), 132.1 (C-5), 131.9 (C-1g), 131.6 (C-1c), 131.1 (C-1e), 129.4
(C-1d), 127.7 (C-7), 127.4 (C-1f), 127.2 (C-4a), 118.7 (C-8), 112.8
(C-8a), 55.5 (C-1a), 52.3 (C-3c), 27.2 (C-6b). IR (neat, cm–1): 3073,
2972, 2941, 1702, 1683. ESI-HRMS m/z [M+H]+ calcd for
C20H16Cl2NO4 404.0451, found 404.0452.
4.2.2. General Method for the Preparation of Amides 4a–j
A mixture of 3 (1 g, 1 eq.), DBU (320 µL, 0.33 g, 2.1 mmol), an
appropriate amine (5 eq.), and chloroform (15 mL) in a 100 mL
round-bottom flask was stirred under reflux for 24–30 h.34 Upon
reaction completion as indicated by TLC, the mixture was evap-
orated to dryness and resultant crude subjected to silica gel
column chromatography eluting with CH2Cl2/MeOH (10:1).
Fractions containing the desired product were combined, evap-
orated to dryness and recrystallized from ethanol. Compounds
4a–j were obtained in 30–50 % yield following this procedure.
6-Acetyl-1-ethyl-N-(2-methoxyethyl)-4-oxo-1,4-dihydroquinoline-3-
carboxamide, 4a
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Orange powder, 0.028 g (32 %), Rf = 0.48 (DCM/MeOH 10:1),
m.p. 163–165 °C; 1H NMR (300 MHz, DMSO) d 9.93 (s, 1H, NH),
8.88 (s, 1H, H-2), 8.83 (d, J = 1.5 Hz, 1H, H-5), 8.32–8.22 (m, 1H,
H-7), 7.97 (d, J = 9.0 Hz, 1H, H-8), 4.55 (q, J = 7.0 Hz, 2H, H-1a),
3.49 (s, 3H, H-3f), 3.42–3.04 (m, 4H, H-3c, H-3d), 2.68 (s, 3H, H-6b),
1.39 (t, J = 7.0 Hz, 3H, H-1b). 13C NMR (75 MHz, DMSO) d 197.6
(C-6a), 175.9 (C-4), 164.2 (C-3a), 148.8 (C-2), 142.1 (C-3), 132.9
(C-6), 132.1 (C-5), 127.9 (C-7), 127.1 (C-4a), 118.4 (C-8), 112.6
(C-8a), 71.3 (C-3d), 58.3 (C-3f), 49.1 (C-1a), 38.8 (C-3c), 27.5 (C-6b),
14.9 (C-1b). IR (neat, cm–1): 3393, 3041, 2970, 2929, 1682, 1656.




White powder, 0.235 g (33 %), Rf = 0.39 (DCM/MeOH 10:1),
m.p. 127–129 °C; 1H NMR (400 MHz, CDCl3) d 10.12 (s, 1H, NH),
8.97 (s, 1H, H-2), 8.75 (s, 1H, H-5), 8.27 (d, J = 7.9 Hz, 1H, H-7), 7.54
(d, J = 7.9 Hz, 1H, H-8), 4.31 (q, J = 7.1 Hz, 2H, H-1a), 3.74-3.61 (m,
8H, H-3c, H-3d, H-3f, H-3g), 2.67 (s, 3H, H-6b), 1.53 (t, J = 7.2 Hz,
3H, H-1b). 13C NMR (101 MHz, CDCl3) d 196.8 (C-6a), 176.7 (C-4),
164.7 (C-3a), 147.9 (C-2), 141.5 (C-3), 133.6 (C-6), 131.9 (C-5), 129.2
(C-7), 127.9 (C-4a), 116.2 (C-8), 113.5 (C-8a), 72.7 (C-3g), 69.7
(C-3f), 61.7 (C-3d), 49.3 (C-1a), 39.0 (C-3c), 26.6 (C-6b), 14.6 (C-1b).
IR (neat, cm–1): 3333, 3252, 3001, 2970, 2929, 1682, 1654. ESI-HRMS
m/z [M+H]+ calcd for C18H23N2O5 347.1601, found 347.1604.
6-Acetyl-1-ethyl-N-(2-((2-hydroxyethyl)amino)ethyl)-4-oxo-1,4-
dihydroquinoline-3-carboxamide, 4c
White powder, 0.475 g (48 %), Rf = 0.11 (DCM/MeOH 10:1),
m.p. 157–159 °C; 1H NMR (300 MHz, DMSO) d 9.97 (t, J = 5.9 Hz,
1H, NH-3b), 8.91 (s, 1H, H-2), 8.84 (d, J = 2.2 Hz, 1H, H-5), 8.30
(dd, J = 9.0, 2.2 Hz, 1H, H-7), 8.01 (d, J = 9.0 Hz, 1H, H-8), 5.27 (s,
1H, H-3h), 4.56 (q, J = 7.1 Hz, 2H, H-1a), 3.67 (t, J = 6.3 Hz, 4H,
H-3d, H-3f), 3.15 (t, J = 8.8 Hz, 2H, H-3g), 3.03 (t, J = 5.4 Hz, 2H,
H-3c), 2.68 (s, 3H, H-6b), 1.39 (t, J = 7.1 Hz, 3H, H-1b). 13C NMR
(75 MHz, DMSO) d 197.2 (C-6a), 175.8 (C-4), 165.1 (C-3a), 149.2
(C-2), 141.8 (C-3), 133.2 (C-6), 132.2 (C-5), 127.6 (C-7), 127.2 (C-4a),
118.5 (C-8), 112.3 (C-8a), 56.9 (C-3g), 49.7 (C-1a), 49.0 (C-3c), 47.1
(C-3f), 35.9 (C-3d), 27.2 (C-6b), 14.9 (C-1b). IR (neat, cm–1): 3313,
3243, 3081, 2879, 2819, 1687, 1656. ESI-HRMS m/z [M+H]+ calcd
for C18H24N3O4 346.1761, found 346.1762.
N-(3-(1H-imidazol-1-yl)propyl)-6-acetyl-1-ethyl-4-oxo-1,4-dihydro-
quinoline-3-carboxamide, 4d
White powder, 0.521 g (57 %), Rf = 0.4 (DCM/MeOH 10:1),
m.p. 207–209 °C; 1H NMR (300 MHz, CDCl3) d 9.98 (s, 1H, NH),
8.99 (s, 1H, H-2), 8.76 (d, J = 0.9 Hz, 1H, H-5), 8.28 (dd, J = 9.0, 0.9
Hz, 1H, H-7), 7.57 (d, J = 9.0 Hz, 1H, H-8), 7.49 (s, 1H, H-3g), 6.99
(d, J = 9.2 Hz, 1H, H-3j), 6.93 (d, J = 9.2 Hz, 1H, H-3i), 4.32 (q, J =
7.2 Hz, 2H, H-1a), 4.01 (t, J = 7.0 Hz, 2H, H-3e), 3.43 (q, J = 6.3 Hz,
2H, H-3c), 2.66 (s, 3H, H-6b), 2.05 (dt, J = 6.8, 6.3 Hz, 2H,
H-3d), 1.54–1.49 (t, J = 7.2 Hz, 3H, H-1b). 13C NMR (75 MHz,
CDCl3) d 196.6 (C-6a), 176.5 (C-4), 164.8 (C-3a), 147.9 (C-2),
141.6 (C-3), 137.2 (C-3g), 133.4 (C-6), 131.7 (C-5), 129.5 (C-3j),
128.9 (C-7), 127.4 (C-4a), 118.9 (C-3i), 116.4 (C-8), 112.9 (C-8a),
49.4 (C-1a), 44.5 (C-3c), 36.1 (C-3e), 31.3 (C-3d), 26.6 (C-6b), 14.6
(C-1b). IR (neat, cm–1): 3303, 3087, 2960, 2912, 1687, 1655.




White powder, 0.432 g (43 %), Rf = 0.4 (DCM/MeOH 10:1), m.p.
136–138 °C; 1H NMR (300 MHz, DMSO) d 9.94 (t, J = 5.0 Hz, 1H,
NH), 9.10 (s, 1H, H-2), 8.86 (d, J = 2.1 Hz, 1H, H-5), 8.19 (dd, J =
9.0, 2.2 Hz, 1H, H-7), 7.79 (d, J = 9.0 Hz, 1H, H-8), 7.62–7.45 (m,
2H, H-1d), 7.29–7.16 (m, 2H, H-1c), 5.79 (s, 2H, H-1a), 3.51 (t, J =
4.6 Hz, 2H, H-3c), 3.48–3.06 (m, 5H, H-3d, H-3f), 2.65 (s, 3H,
H-6b). 13C NMR (75 MHz, DMSO) d 197.1 (C-6a), 176.2 (C-4),
164.1 (C-3a), 150.2 (C-2), 142.2 (C-3), 135.7 (C-1b), 133.3 (C-6),
132.3 (C-5), 132.0 (C-1c), 129.2 (C-1d), 127.7 (C-7), 127.3 (C-1e),
121.5 (C-4a), 118.9 (C-8), 112.7 (C-8a), 71.2 (C-3d), 58.5 (C-3f), 55.8
(C-1a), 38.8 (C-3c), 27.2 (C-6b). IR (neat, cm–1): 3317, 3051, 2960,




White powder, 0.20 g (48 %), Rf = 0.11 (DCM/MeOH 10:1), m.p.
178–180 °C; 1H NMR (300 MHz, DMSO) d 9.93 (t, J = 4.8 Hz, 1H,
NH), 9.10 (s, 1H, H-2), 8.85 (d, J = 1.7 Hz, 1H, H-5), 8.19 (dd, J =
8.9, 1.7 Hz, 1H, H-7), 7.79 (d, J = 9.0 Hz, 1H, H-8), 7.54 (d, J = 8.3
Hz, 2H, H-1d), 7.20 (d, J = 8.3 Hz, 2H, H-1c), 5.79 (s, 2H, H-1a),
4.62 (t, J = 5.2 Hz, 2H, H-3c), 3.60–3.49 (m, 6H, H-3d, H-3f,
H-3g), 2.43 (s, 3H, H-6b). 13C NMR (75 MHz, DMSO) d 197.1
(C-6a), 176.2 (C-4), 164.1 (C-3a), 150.2 (C-2), 142.2 (C-3), 135.7
(C-1d), 133.4 (C-6), 132.2 (C-1c), 132.0 (C-5), 129.3 (C-7), 127.4
(C-1b), 121.6 (C-4a), 118.9 (C-8), 112.7 (C-8a), 111.9 (C-1e),
58.7 (C-3g), 55.8 (C-1a), 49.4 (C-3f), 48.9 (C-3d), 36.9 (C-3c), 27.2
(C-6b). IR (neat, cm–1): 3320, 3202, 3000, 2970, 2929, 1682, 1657.
ESI-HRMS m/z [M+H]+ calcd for C23H25BrN3O4 486.1023, found
486.1021.
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White powder, 0.20 g (48 %), Rf = 0.4 (DCM/MeOH 10:1), m.p.
183–185 °C; 1H NMR (300 MHz, DMSO) d 9.93 (t, J = 4.8 Hz, 1H,
NH), 9.10 (s, 1H, H-2), 8.85 (d, J = 1.7 Hz, 1H, H-5), 8.19 (dd, J =
8.9, 1.7 Hz, 1H, H-7), 7.79 (d, J = 9.0 Hz, 1H, H-8), 7.54 (d, J = 8.3
Hz, 2H, H-1d), 7.20 (d, J = 8.3 Hz, 2H, H-1c), 5.79 (s, 2H, H-1a),
4.62 (t, J = 5.2 Hz, 2H, H-3c), 3.60–3.49 (m, 6H, H-3d, H-3f, H-3g),
2.43 (s, 3H, H-6b). 13C NMR (75 MHz, DMSO) d 197.1 (C-6a), 176.2
(C-4), 1- 64.1 (C-3a), 150.2 (C-2), 142.2 (C-3), 135.7 (C-1d), 133.4
(C-6), 132.2 (C-1c), 132.0 (C-5), 129.3 (C-7), 127.4 (C-1b), 121.6
(C-4a), 118.9 (C-8), 112.7 (C-8a), 111.9 (C-1e), 72.7 (C-3d), 69.7
(C-3f), 60.7 (C-3g), 55.0 (C-1a), 39.7 (C-3c), 27.2 (C-6b). IR (neat,
cm–1): 3397, 3252, 3041, 2950, 2861, 1686, 1654. ESI-HRMS m/z
calcd for C23H24BrN2O5 487.0863, found 487.0665 [M+H]
+. HPLC
purity > 96 %, retention time = 9.89 min.
6-Acetyl-1-benzyl-N-(2-((2-hydroxyethyl)amino)ethyl)-4-oxo-1,4-
dihydroquinoline-3-carboxamide, 4h
Orange powder, 0.320 g (48 %), Rf = 0.11 (DCM/MeOH 10:1),
m.p. 169–171 °C; 1H NMR (300 MHz, DMSO) d 9.93 (t, J = 4.8 Hz,
1H, NH), 9.10 (s, 1H, H-2), 8.85 (d, J = 1.7 Hz, 1H, H-5), 8.19 (dd,
J = 8.9, 1.7 Hz, 1H, H-7), 7.79 (d, J = 9.0 Hz, 1H, H-8), 7.54-7.20 (m,
5H, H-1c, H-1d, H-1f, H-1g), 5.79 (s, 2H, H-1a), 4.62 (t, J = 5.2 Hz,
2H, H-3c), 3.60–3.49 (m, 6H, H-3d, H-3f, H-3g), 2.43 (s, 3H, H-6b).
13C NMR (75 MHz, DMSO) d 197.1 (C-6a), 176.2 (C-4), 164.1
(C-3a), 150.2 (C-2), 142.2 (C-3), 135.7 (C-1d), 133.4 (C-6), 132.2
(C-1c), 132.0 (C-5), 129.3 (C-7), 127.4 (C-1b), 121.6 (C-4a), 118.9
(C-8), 112.7 (C-8a), 111.9 (C-1e), 72.7 (C-3d), 69.7 (C-3f), 60.7
(C-3g), 55.02 (C-1a), 39.7 (C-3c), 27.2 (C-6b). IR (neat, cm–1): 3328,
3212, 3038, 2971, 2921, 1682, 1659. ESI-HRMS m/z [M+H]+ calcd
for C23H26N3O4 408.1918, found 408.1923.
6-Acetyl-1-(2,4-dichlorobenzyl)-N-(2-methoxyethyl)-4-oxo-1,4-dihy-
droquinoline-3-carboxamide, 4i
Brown powder, 0.370 g (44 %), Rf = 0.4 (DCM/MeOH 10:1).
m.p. 203–205 °C; 1H NMR (300 MHz, DMSO-d6) d 9.99 (t, J = 5.1
Hz, 1H, NH), 9.16 (s, 1H, H-2), 8.92 (d, J = 2.2 Hz, 1H, H-5), 8.26
(dd, J = 8.9, 2.2 Hz, 1H, H-7), 7.85 (d, J = 9.0 Hz, 1H, H-8),
7.72–7.59 (m, 2H, H-1d, H-1f), 7.21 (d, J = 8.3, Hz, 1H, H-1g), 5.87
(s, 2H, H-1a), 3.56–3.13 (m, 4H, H-3c, H-3d), 3.37 (s, 3H, H-3f), 2.70
(s, 3H, H-6b). 13C NMR (75 MHz, DMSO) d 197.1 (C-6a), 176.3
(C-4), 164.0 (C-3a), 150.2 (C-2), 142.1 (C-3), 137.4 (C-6), 133.4
(C-1b), 132.1 (C-5), 131.9 (C-1g), 131.6 (C-1c), 131.1 (C-1e), 129.4
(C-1d), 127.7 (C-7), 127.4 (C-1f), 127.2 (C-4a), 118.7 (C-8), 112.8
(C-8a), 71.2 (C-3d), 58.5 (C-3f), 55.3 (C-1a), 39.0 (C-3c), 27.2 (C-6b).
IR (neat, cm–1): 3298, 3071, 2971, 2929, 1682, 1655. ESI-HRMS m/z
[M+H]+ calcd for C22H21Cl2N2O4 447.0873, found 447.0878.
6-Acetyl-N-(2-((2-hydroxyethyl)amino)ethyl)-4-oxo-1-(4-(trifluoro-
methyl)benzyl)-1,4-dihydroquinoline-3-carboxamide, 4j
Orange powder, 0.367 g (44 %), Rf = 0.11 (DCM/MeOH 10:1),
m.p. 193–195 °C; 1H NMR (300 MHz, DMSO) d 10.03 (t, J = 5.9 Hz,
1H, NH), 9.22 (s, 1H, H-2), 8.92 (d, J = 2.1 Hz, 1H, H-5), 8.28 (dd,
J = 8.9, 2.2 Hz, 1H, H-7), 7.87 (d, J = 9.0 Hz, 1H, H-8), 7.79 (d,
J = 8.1 Hz, 2H, H-1c), 7.51 (d, J = 8.0 Hz, 2H, H-1d), 6.03 (s, 2H,
H-1a), 5.36 (t, J = 5.1 Hz, 1H, OH), 3.83–3.70 (m, 4H, H-3d, H-3f),
3.22 (t, J = 6.3 Hz, 2H, H-3c), 3.11 (t, J = 5.3 Hz, 2H, H-3g), 2.70 (s,
3H, H-6b). 13C NMR (75 MHz, DMSO) d 197.1 (C-6a), 176.1 (C-4),
165.0 (C-3a), 150.4 (C-2), 142.2 (C-3), 141.1 (C-1b), 133.5 (C-6),
132.4 (C-5), 129.1 (C-1e), 127.7 (C-7), 127.4 (C-1c), 127.3 (C-1d),
126.3 (C-1f), 126.3 (C-4a), 118.9 (C-8), 112.6 (C-8a), 56.9 (C-3g),
55.9 (C-1a), 49.6 (C-3f), 47.0 (C-3d), 35.9 (C-3c), 27.2 (C-6b). IR
(neat, cm–1): 3293, 3252, 3081, 2974, 2926, 1682, 1654. ESI-HRMS
m/z [M+H]+ calcd for C24H25F3N3O4 476.1792, found 476.1797.
4.3. In vitro Anti-trypanosomal Assay
Trypanosoma brucei brucei 427 trypomastigotes were cultured in
Iscove’s Modified Dulbecco’s Medium (IMDM; Lonza) supple-
mented with 10 % fetal calf serum,35 HMI-9 supplement,
hypoxanthine and penicillin/streptomycin at 37 °C in a 5 % CO2
incubator. Serial dilutions of test compounds were incubated
with the parasites in 96-well plates for 24 h and residual parasite
viability in the wells determined by adding 20 µL of 0.54 mM
resazurin in phosphate buffered saline (PBS) and incubating
for an additional 2–4 h. Reduction of resazurin to resorufin by
viable parasites was assessed by fluorescence readings (excita-
tion 560 nm, emission 590 nm) in a Spectramax M3 plate reader.
Fluorescence readings were converted to % parasite viability rel-
ative to the average readings obtained from untreated control
wells. IC50 values were determined by plotting % viability vs.
log[compound] and performing non-linear regression using
GraphPad Prism (v. 5.02) software.
4.4. In vitro Cytotoxicity Assay
HeLa cells (Cellonex) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Lonza) supplemented with 10 % fetal
calf serum and antibiotics (penicillin/streptomycin/ampho-
tericin B) at 37 ºC in a 5 % CO2 incubator. Cells were plated in
96-well plates at a cell density of 2 × 104 cells per well and grown
overnight. Serial dilutions of test compounds were incubated
with the cells for an additional 24 h, and cell viability in the
wells assessed by adding 20 µL 0.54 mM resazurin in PBS for an
additional 2–4 h. Fluorescence readings (excitation 560 nm, emis-
sion 590 nm) obtained for the individual wells were converted
to % cell viability relative to the average readings obtained from
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untreated control wells. Plots of % cell viability vs. log[com-
pound] were used to determine IC50 values by non-linear regres-
sion using GraphPad Prism (v. 5.02).
Supplementary Material
Supplementary information is provided in the online supple-
ment.
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Figure S11a: Compounds inhibitory potential against T.b. brucei parasites at 20µM. 
Compounds were added to in vitro cultures of T.b. brucei in 96-well plates at a fixed 
concentration of 20 µM. After an incubation period of 48 hours, the numbers of parasites 
surviving drug exposure were determined by adding resazurin.  Reduction of resazurin to 
resorufin by living cells was quantified in a multiwell fluorescence plate reader 
(Exc560/Em590). The results are expressed as parasite % viability relative to untreated controls. 
Compounds were tested in duplicate wells, and a standard deviation (SD) calculated. Only 
compounds exhibiting less than 20% parasite viability were considered for IC50 
determination. 
 
Figure S11b: Compounds inhibitory potential against T.b. brucei parasites at 20µM. 
Compounds were added to in vitro cultures of T.b. brucei in 96-well plates at a fixed 
concentration of 20 µM. After an incubation period of 48 hours, the numbers of parasites 
surviving drug exposure were determined by adding resazurin.  Reduction of resazurin to 
resorufin by living cells was quantified in a multiwell fluorescence plate reader 
(Exc560/Em590). The results are expressed as parasite % viability relative to untreated controls. 
Compounds were tested in duplicate wells, and a standard deviation (SD) calculated. Only 




Figure SI2a: Compound cytotoxicity against HeLa cells at 20µM. 
Compounds were added to in vitro cultures of HeLa (human cervix adenocarcinoma) cells in 
96-well plates at a fixed concentration of 20 µM. After an incubation period of 48 hours, the 
numbers of cells surviving drug exposure are determined by adding resazurin, which was 
reduced to resorufin by living cells. Resorufin was quantified in a multiwell fluorescence 
plate reader (Exc560/Em590). The results are express as cell % viability. Compounds were 
tested in duplicate wells, and a standard deviation (SD) calculated. With the exception of 
compound RB009, this series shows no extensive cytotoxicity against HeLa cells. 
  
 
Figure SI2b: Compound cytotoxicity against HeLa cells at 20µM. 
Compounds were added to in vitro cultures of HeLa (human cervix adenocarcinoma) cells in 
96-well plates at a fixed concentration of 20 µM. After an incubation period of 48 hours, the 
numbers of cells surviving drug exposure are determined by adding resazurin which was 
reduced to resorufin by living cells. Resorufin is was quantified in a multiwell fluorescence 
plate reader (Exc560/Em590). The results are express as cell % viability. Compounds were 
tested in duplicate wells, and a standard deviation (SD) calculated. With the exception of 
compound RB025, this series shows no cytotoxicity against HeLa cells. 
